- subcutaneous
BPC-157
Body Protection Compound-157
BPC-157 at a glance
Nomination withdrawnHow studies gave it
Injected into the fat under the skin
Evidence on this page
3 peer-reviewed papers, published 1997 to 2011
FDA compounding lists
It was nominated for compounding use and the nomination was withdrawn.
Mixing it
BPC-157 reconstitution calculatorWhat it is
BPC-157 is a synthetic peptide consisting of 15 amino acids, derived from a partial sequence of a protein found in human gastric juice. It has been studied in animal models in the context of tissue repair, tendon and ligament healing, and gastrointestinal protection. Preclinical research has explored its potential interactions with nitric oxide and growth factor pathways. It is frequently discussed in biohacking and longevity communities.
Published research
BPC-157 has been the subject of extensive preclinical research, primarily in rodent models. Published studies have investigated its effects on tendon-to-bone healing, muscle injury recovery, gastrointestinal mucosal integrity, and vascular function. Several papers describe interactions with the nitric oxide system and various growth factor pathways.
As of the current date, no completed human clinical trials have been published in peer-reviewed journals. All dosing information available in community forums is extrapolated from animal study data.
What the terms on this page mean5 termsHide
- peptide
- A short chain of amino acids, the building blocks of proteins.
- amino acid
- A building block that links with others to form peptides and proteins.
- animal model
- A test in animals standing in for the human condition. Results often fail to carry over to people.
- preclinical
- Laboratory and animal work done before any testing in people.
- clinical trial
- A study that tests something in people under a written plan, with results recorded.
Compounding status
Nomination withdrawn- FDA lists it as
- BPC-157
- What that means
- These substances are not eligible for the policy that applies to substances in category 1. FDA would consider taking action against a compounder for compounding drug products with this bulk drug substance under its general enforcement policies.
Source: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA. Content current as of 2026-04-22; read 2026-09-05. This describes what a compounding pharmacy may supply. It is not advice about your own use.
Also given subcutaneous
- CagriSemaCagriSema (Cagrilintide + Semaglutide)Not on either FDA list
- CJC-1295CJC-1295 (with and without DAC)Nomination withdrawn
- CJC-1295 DACCJC-1295 with Drug Affinity Complex (DAC:GRF)Nomination withdrawn
- DihexaN-hexanoic-Tyr-Ile-(6)-aminohexanoic amide (PNB-0408)Nomination withdrawn
- DSIPDelta Sleep-Inducing Peptide (Emideltide)Nomination withdrawn
- EpithalonEpithalon (Epitalon / AEDG Peptide)Nomination withdrawn
Where this came from3 referencesHide
Each one was resolved at PubMed and confirmed to be the work this page cites. Author, title, journal and year come from the PubMed record, not from the page text.
- Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract
Sikiric P, et al.. Current pharmaceutical design (2011). PMID 21548867.
- The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
Chang CH, et al.. Journal of applied physiology (Bethesda, Md. : 1985) (2011). PMID 21030672.
- BPC 157's effect on healing
Seiwerth S, et al.. Journal of physiology, Paris (1997). PMID 9403790.
About this page
Reviewed 2026-08-11. This page reports what published studies and FDA documents say. It carries no dose, cycle length or stack, and it does not tell you whether a substance is appropriate for you. Side-effect reports circulating on forums are self-reported rather than measured, so they are not republished here.
See the editorial policy for how corrections are handled.